David Hallett - 06 Feb 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Scientific Officer
Signature: /s/ Kyle Nelson, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 06 Feb 2026
Net transactions value: -$45,372
Form type: 4
Filing time: 10 Feb 2026, 18:18:12 UTC
Previous filing: 09 Jan 2026
Next filing: 19 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hallett David	Chief Scientific Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY	/s/ Kyle Nelson, attorney-in-fact	10 Feb 2026	0002006495

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+502,064	+85%	$0.000000	1,096,205	06 Feb 2026	Direct	F1
transaction	RXRX	Class A Common Stock	Award	$0	+24,254	+2.2%	$0.000000	1,120,459	06 Feb 2026	Direct	F2
transaction	RXRX	Class A Common Stock	Tax liability	$45,372	-11,400	-1%	$3.98	1,109,059	06 Feb 2026	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2026 and every three months thereafter.
F2	This RSU vested immediately upon the grant date.
F3	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.